Abstract
The relaxing effect of the phosphodiesterase type 5 (PDE5) inhibitors on vascular smooth muscle has attracted much attention, especially in persons with cardiovascular disease. The results of early studies showed that sildenafil slightly reduces systolic and diastolic blood pressures and has no effect on heart rate, while being safe and well tolerated. Studies also indicate that sildenafil does not contribute to the development of myocardial infarction or ischemia. Similar benign effects on hemodynamics and cardiac events have also been demonstrated for tadalafil and vardenafil. None of the PDE5 inhibitors adversely affects total exercise time or time to ischemia during exercise testing in men with stable angina. It is key to avoid concomitant administration of nitrates with any of the PDE5 inhibitors, because this combination can cause increased vasodilation and a subsequent drop in blood pressure. Sildenafil has an alpha‐blocker precaution; tadalafil is contraindicated with alpha blockers except for 0.4 mg tamsulosin; vardenafil is contraindicated with alpha blockers.
Keywords: phosphodiesterase type 5 inhibitors, sildenafil, tadalafil, vardenafil, nitrates, hemodynamic effects, myocardial infarction, ischemia
Full Text
The Full Text of this article is available as a PDF (66.7 KB).
References
- 1. Zusman RM, Morales A, Glasser DB, Osterloh IH: Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 1999; 83: 35C‐44C [DOI] [PubMed] [Google Scholar]
- 2. Cialis® (tadalafil) (package insert). Indianapolis, Ind. and Bothell, Wash.: Lilly ICOS LLC; 2003. [Google Scholar]
- 3. Emmick JT, Stuewe SR, Mitchell M: Overview of the cardiovascular effects of tadalafil. Eur Heart J Suppl 2002; 4 (suppl H): H32–H47 [Google Scholar]
- 4. Kloner RA, Mitchell M, Emmick JT: Cardiovascular effects of tadalafil. Am J Cardiol 2003; 92 (suppl): 37M–46M [DOI] [PubMed] [Google Scholar]
- 5. Stark S, Sachse R, Liedl T, Hensen J, Rohde G, Wensing G, Horstmann R, Schrott KM: Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur Urol 2001; 40: 181–190 [DOI] [PubMed] [Google Scholar]
- 6. Jackson G, Betteridge J, Dean J, Hall R, Holdright D, Holmes S, Kirby M, Riley A, Sever P: A systematic approach to erectile dysfunction in the cardiovascular patient: A consensus statement. Int J Clin Pract 1999; 53: 445–451 [PubMed] [Google Scholar]
- 7. Kloner RA, Mitchell MI, Bedding A, Emmick J: Pharmacodynamic interactions between tadalafil and nitrates compared with sildenafil (abstr 708). J Urol 2002; 167 (suppl): 176–177 [Google Scholar]
- 8. Kloner RA, Emmick J, Bedding A, Humen D: Pharmacodynamic interactions between tadalafil and nitrates (abstr 291A). J Am Coll Cardiol 2002; 39 (suppl A) [Google Scholar]
- 9. Levitra® (vardenafil) (package insert). West Haven, Conn: Bayer Pharmaceuticals Corp., 2003. [Google Scholar]
- 10. Kloner RA, Hutter AM, Emmick JT, Mitchell MI, Denne J, Jackson G: Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 2003; 42: 1855–1860 [DOI] [PubMed] [Google Scholar]
- 11. Padma‐Nathan H, Eardley I, Kloner RA, Laties AM, Montorsi F: A 4‐year update on the safety of sildenafil citrate (Viagra®). Urology 2002; 60 (suppl 2B): 67‐90 [DOI] [PubMed] [Google Scholar]
- 12. Viagra® (sildenafil) (package insert). New York, NY: Pfizer Inc., 2003. [Google Scholar]
- 13. Arruda‐Olson A, Mahoney DW, Nehra A, Leckel M, Pellikka PA: Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease. A randomized crossover trial. J Am Med Assoc 2002; 287: 719–725 [DOI] [PubMed] [Google Scholar]
- 14. Thadani U, Smith W, Nash S, Bittar N, Glasser S, Narayan P, Stein RA, Larkin S, Mazzu A, Tota R, Pomerantz K, Sundaresan P: The effect of vardenafil, a potent and highly selective phosphodi‐esterase‐5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol 2002; 40: 2006–2012 [DOI] [PubMed] [Google Scholar]
- 15. Patterson D, MacDonald TM, Effron MB, Emmick JT, Mitchell MI, Kloner RA: Tadalafil does not affect time to ischemia during exercise stress testing in patients with coronary artery disease (abstr 1650). Circulation 2002; 106 (suppl): 330 [Google Scholar]
- 16. Boshier A, Wilton LV, Shakir SAW: Cardiovascular events in a cohort study of sildenafil users in England. Poster presented at 5th Congress of the European Society for Sexual and Impotence Research, Hamburg, Germany, December 1‐4, 2002.
- 17. Sadovsky R, Miller T, Moskowitz M: Three‐year update of sildenafil citrate (Viagra®) efficacy and safety. Int J Clin Pract 2001; 55: 115–128 [PubMed] [Google Scholar]
- 18. Alpaslan M, Onrat E, Samli M, Dincel C: Sildenafil citrate does not affect QT intervals and QT dispersion: An important observation for drug safety. Ann Noninvas Electrocardiol 2003; 8: 14–17 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Sofowora G, Dishy V, Roden D, Wood AJJ, Stein CM: The effect of sildenafil on QT interval in healthy men (abstr PIII‐11). Clin Pharmacol Ther 2001; 69: P67 [DOI] [PubMed] [Google Scholar]
- 20. Data on file. Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee : Levitra® tablets. Available at: http://www.fda.gov/ohrms/dockets/ac/03/slides/3956S1_03_Bayer.ppt. Accessed September 5, 2003.
- 21. Kloner RA, Mitchell M, Emmick JT: Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol 2003; 92 (suppl): 47M–57M [DOI] [PubMed] [Google Scholar]
- 22. Webb DJ, Freestone S, Allen MJ, Muirhead GJ: Sildenafil citrate and blood pressure‐lowering drugs: Results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol 1999; 83: 21C–28C [DOI] [PubMed] [Google Scholar]
- 23. Kloner RA, Brown M, Prisant LM, Collins M: Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Am J Hypertens 2001; 14: 70–73 [DOI] [PubMed] [Google Scholar]
- 24. Rohde G, Jordaan PJ: Influence of vardenafil on blood pressure and pharmacokinetics in hypertensive patients on nifedipine therapy (abstr). Pharmacotherapy 2002; 22: 418 [Google Scholar]
- 25. Padma‐Nathan H, Porst H, Eardley T, Thibonnier M: Efficacy and safety of vardenafil, a selective phosphodiesterase 5 inhibitor, in men with erectile dysfunction on antihypertensive therapy (abstr). Am J Hypertens 2002; 15 (suppl): 48A 11824860 [Google Scholar]